DNA Wars in Cambridge

Three Cambridge biotech startups are vying for control of a revolutionary gene-editing tool called CRISPR-Cas9. On the line are a billion-dollar market, a potential Nobel Prize, and, yes, the power to resurrect an extinct species.

Read the story at Boston Magazine.